Biomarker set for identifiying a severe form of cancer
Breast cancer has been recognized as a heterogeneous
disease that consists of different intrinsic subtypes, including hormone receptor positive breast cancer (also known as luminal breast cancer), which accounts for 70-80% of newly diagnosed breast tumors. The histologic grade of luminal breast cancer is often determined by semi-quantitative methods describing morphologic features related to the differentiation states of the tumor specimen, ranging from well differentiated “grade 1” tumors, through intermediate differentiation (“grade 2”) to poorly differentiated “grade 3” tumors. Breast tumors characterized as luminal “grade 3” generally respond well to chemotherapeutic treatments, whereas patients with luminal “grade 1” tumors would be overtreated. In order to make a clear-cut classification of luminal breast cancer as either “grade 1” (= low risk) or “grade 3” (= high risk) tumors, DKFZ researchers have developed a 3-protein marker set.
Further Information: PDF
DKFZ (German Cancer Research Center, Deutsches Krebsforschungszentrum)
Phone: +49-6221-42 2955
Contact
Dr. Ruth Herzog
Media Contact
All latest news from the category: Technology Offerings
Newest articles
Microscopic basis of a new form of quantum magnetism
Not all magnets are the same. When we think of magnetism, we often think of magnets that stick to a refrigerator’s door. For these types of magnets, the electronic interactions…
An epigenome editing toolkit to dissect the mechanisms of gene regulation
A study from the Hackett group at EMBL Rome led to the development of a powerful epigenetic editing technology, which unlocks the ability to precisely program chromatin modifications. Understanding how…
NASA selects UF mission to better track the Earth’s water and ice
NASA has selected a team of University of Florida aerospace engineers to pursue a groundbreaking $12 million mission aimed at improving the way we track changes in Earth’s structures, such…